Fabrazyme (Agalsidase Beta Vials) 35mg

Agalsidase Beta, the active ingredient in Fabrazyme, works by replacing the deficient alpha-galactosidase A enzyme in patients with Fabry disease. This enzyme is responsible for breaking down globotriaosylceramide (GL-3), a fatty substance that accumulates in the body's cells due to the enzyme deficiency. By providing the missing enzyme, Fabrazyme helps to hydrolyze the accumulated GL-3, reducing its harmful effects on various organs and tissues.

The recommended dosage for Fabrazyme is 1 mg/kg of body weight given once every two weeks. The prescriber will determine the appropriate dose based on the patient's individual needs and response to the treatment. It is important to follow the prescriber's instructions and not to adjust the dose without consulting them.

Experience with the use of Fabrazyme in pregnant women is limited. As a precaution, it is recommended to avoid the use of Fabrazyme during pregnancy. Fabrazyme passes into breast milk. Talk to your doctor about the risks and benefits of breastfeeding versus continuing treatment with Fabrazyme. No studies have been conducted to examine the effects of Fabrazyme on fertility.

To order Fabrazyme from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping (including cold-chain where relevant), and the import paperwork.

Fabrazyme and Galafold are both used in the treatment of Fabry disease, but they work in different ways. Fabrazyme is an enzyme replacement therapy that provides the missing alpha-galactosidase A enzyme, while Galafold is a small molecule that stabilizes the existing enzyme. The choice between these treatments depends on the patient's individual needs and response to the treatment.

Fabrazyme should be stored in a refrigerator (between 2°C and 8°C). The reconstituted solution should not be stored and should be diluted promptly. The diluted solution can be stored for a maximum of 24 hours at a temperature between 2°C and 8°C. It is important to follow the storage and handling instructions provided with the medication to ensure its effectiveness and safety.

Fabrazyme is administered by intravenous infusion. The medication is reconstituted with water for injections and diluted with sodium chloride 0.9% injection solution before administration. The infusion rate can be increased gradually based on the patient's tolerance. It is important to follow the administration instructions provided by the healthcare provider.

The most serious risks to watch for with Fabrazyme include infusion-related reactions, allergic reactions, hypersensitivity reactions, and anaphylaxis. These reactions can be severe and may require immediate medical attention. It is important to inform your healthcare provider if you experience any unusual symptoms during or after the infusion.

Fabrazyme should not be used by patients who are allergic to agalsidase beta or any of the other ingredients in the medication. It should also be used with caution in patients with a history of severe infusion-related reactions. Pregnant women should avoid using Fabrazyme unless necessary, and breastfeeding women should consult their doctor about the risks and benefits of continuing treatment with Fabrazyme.